5 Best Performing Biotech ETFs in 2024

Page 5 of 5

1. VanEck Biotech ETF (NASDAQ:BBH)

5-Year Share Price Performance as of April 20: 23.40%

The VanEck Biotech ETF (NASDAQ:BBH) seeks to replicate the performance of the MVIS US Listed Biotech 25 Index, which comprises companies involved in the development, production, marketing, and sales of drugs utilizing genetic analysis and diagnostic equipment. Established on December 20, 2011, the fund boasts net assets totaling $410.74 million as of April 19.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) holds a prominent position among the top holdings of the VanEck Biotech ETF (NASDAQ:BBH). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company primarily focused on developing and commercializing therapies for cystic fibrosis. On February 13, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the European Commission granted conditional marketing authorization to CASGEVY for the treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia (TDT).

In the fourth quarter of 2023, 62 out of the 933 hedge funds examined by Insider Monkey held shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The largest stake was held by Cliff Asness’ AQR Capital Management, valued at $262.34 million.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out 10 Best Real Estate ETFs To Buy Now and 11 Best EV Stocks To Buy For The Long Term.

Page 5 of 5